Efficacy of nilotinib in second line in an elderly patient with CML, suboptimal response and multiple comorbidities

Efficacy of nilotinib in second line in an elderly patient with CML, suboptimal response and multiple comorbidities

Authors

  • Carmen Tomaselli U.O. di Ematologia con TMO, A.R.N.A.S. Civico Palermo


DOI:

https://doi.org/10.7175/cmi.v7i1S.1145

Keywords:

Chronic myeloid leukemia, Monitoring, Imatinib, Nilotinib, Comorbidities Keywords, Comorbidities

Abstract

In this case report we describe the clinical case of an elderly patient with chronic myeloid leukemia and multiple comorbidities (heart disease, diabetes). Following the diagnosis of CML, in 2005 the patient had started treatment with imatinib 400 mg / day; therapy was well tolerated and never suspended until 2011, when he comes to the attention of our center. After re-evaluation of the disease, the patient is considered "failure" according to the recommendations ELN 2009. For this reason he switched to second generation tyrosine kinase inhibitor, nilotinib. After just 3 months of treatment with nilotinib the patient gets a complete cytogenetic response and a reduction of the transcript BCR/ABL %IS from 0,85 to 0,004. These results are still maintained, without any influence on pre-existing conditions.

Downloads

Published

2015-10-13

Issue

Vol. 7 No. 1S (2013)

Section

Case report

License

Authors who publish with this journal agree to the following terms:
    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution Non-Commercial 4.0 Licence that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
    2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. The Publication Agreement can be downloaded here, and should be signed by the Authors and sent to the Publisher when the article has been accepted for publication in this journal.
    3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
    4. Authors are permitted to post their work online after publication (the article must link to publisher version, in html format)